Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

16.1%

5 terminated/withdrawn out of 31 trials

Success Rate

73.7%

-12.8% vs industry average

Late-Stage Pipeline

19%

6 trials in Phase 3/4

Results Transparency

7%

1 of 14 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

N/A
10(45.5%)
Phase 2
5(22.7%)
Phase 4
5(22.7%)
Phase 3
1(4.5%)
Phase 1
1(4.5%)
22Total
N/A(10)
Phase 2(5)
Phase 4(5)
Phase 3(1)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (31)

Showing 20 of 31 trials
NCT06394284Phase 3Recruiting

Examining 3,4-methylenedioxymethamphetamine (MDMA) Effects on Psychological, Relational and Hyperarousal-Related Neural Reactivity Mechanisms in Veterans With PTSD and Moral Injury

Role: lead

NCT02960347Not ApplicableCompleted

Examining the Efficacy of tDCS in the Attenuation of Epileptic Paroxysmal Discharges and Clinical Seizures

Role: lead

NCT03702933Unknown

D-serine in Schizophrenia

Role: lead

NCT01804920Not ApplicableUnknown

D-Serine Treatment For Tardive Dyskinesia

Role: lead

NCT02987634Phase 4Unknown

Evaluation and Comparison of Efficacy of PeriActive Mouthwash to Chlorhexidine 0.12% Mouth Rinse

Role: collaborator

NCT03376750Not ApplicableUnknown

Tele-rehabilitation Intervention for People Post Hip Fracture - Randomized Controlled Trial (RCT)

Role: lead

NCT03300219Not ApplicableUnknown

Tele-rehabilitation Intervention for People Post Hip Fracture - Pilot Study

Role: lead

NCT00447174Not ApplicableCompleted

Parental Bereavement Study Among Couples Coping Traumatic Loss of a Child

Role: lead

NCT02657720Phase 4Completed

Comparison Between Different Technologies That Measure Respiratory Rate

Role: collaborator

NCT02227563Not ApplicableTerminated

tDCS & Auditory Hallucinations in Schizophrenia

Role: lead

NCT02657733Phase 4Completed

Comparison Study Between Nellcor Respiration Rate Technology (RRoxi) and Masimo Acoustic Respiration Rate (RRa)

Role: collaborator

NCT00784771Not ApplicableCompleted

Hypnotherapeutic Olfactory Conditioning for Posttraumatic Stress Disorder (PTSD)

Role: lead

NCT02051426Not ApplicableCompleted

Behavioral and Cognitive Effects of the N-methyl-D-aspartate Receptor (NMDAR) Co-agonist D-serine in Healthy Humans

Role: lead

NCT00276263Phase 2Withdrawn

Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia

Role: lead

NCT00425399Not ApplicableCompleted

Shiatsu Adjuvant Therapy For Schizophrenia

Role: lead

NCT00816894Phase 2Completed

D-serine Monotherapy for Schizophrenia

Role: lead

NCT00463138Completed

Follow-up Study on Recipients of Treatment at the Jerusalem Center for the Treatment of Psychotrauma

Role: lead

NCT00600418Completed

Identifying Toddlers and Their Parents Who Are Suffering From Posttraumatic Distress Following War and Terror

Role: lead

NCT00447538Completed

Posttraumatic Symptoms Among Toddlers and Their Parents Following Exposure to Terrorism

Role: lead

NCT00313417Phase 4Terminated

Creatine as a New Therapeutic Strategy in Depression

Role: lead